Chao Gao

Showing 1-3 of 3 articles

A randomised controlled trial of the sirolimus-eluting biodegradable polymer ultra-thin Supraflex stent versus the everolimus-eluting biodegradable polymer SYNERGY stent for three-vessel coronary artery disease: rationale and design of the Multivessel TALENT trial

Hara H, Gao C, Kogame N, Ono M, Kawashima H, Wang R, Morel M, O'Leary N, Sharif F, Möllmann H, Reiber J, Sabaté M, Zaman A, Wijns W, Onuma Y, Serruys PW

December 18, 2020 | 10.4244/EIJ-D-20-00772

Valvular heart interventions: advances from 2019 to 2020

Wang R, Gao C, Kawashima H, Modolo R, Rosseel L, Onuma Y, Soliman O, Serruys PW, Mylotte D

November 20, 2020 | 10.4244/EIJ-D-20-00096

The year in review: coronary interventions

Gao C, Wang R, Sharif F, Takahashi K, Ono M, Hara H, Tomaniak M, Kawashima H, Modolo R, van Geuns R, Capodanno D, Byrne R, Wijns W, Onuma Y, Serruys PW

April 17, 2020 | 10.4244/EIJ-D-19-01124

1

Latest news

State-of-the-Art on Coronary Physiology; a Mini Focus on Biostatistics; Post-TAVI Aortic Manipulation; Minimally Invasive Ventricular Reconstruction after MI

Don't miss the next #EIJCardioChat!

IVUS-guided stenting in VIV-TAVI

This Week's JAA's: Deep Learning Model to Detect AMI, Mortality After Bleeding vs MI in CAD Patients...

New update: EXAMINATION 10 years, BIONYX 2 years, SAFE A, MASH and more

(Thanks to the support of Biotronik)

Optimising Physiological Endpoints of Percutaneous Coronary Intervention

Reducing refractory angina

Ranil de Silva et al.

Discover EuroIntervention's New Author Centre

Valvular disease